newsfilter
← Latest News
Business Wire·

Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

INBRIJA® (levodopa inhalation powder) 2022 U.S. net revenue of $28.0MM and ex-U.S. net revenue of $2.9MM; Q4 2022 U.S. net revenue of $9.0MM AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2022 net